Philip Toleikis
Chief Tech/Sci/R&D Officer chez SERNOVA CORP.
Fortune : 2 M $ au 31/03/2024
Profil
Philip M.
Toleikis is currently the Director & Chief Technology Officer at Sernova Corp.
since 2023.
He is also a Member of the Medway Working Group.
Previously, he worked as the VP-Pharmacology, Research & Development at Angiotech Pharmaceuticals, Inc. from 1999 to 2006.
Dr. Toleikis holds a doctorate degree from the University of British Columbia, a graduate degree from the University of Michigan, and an undergraduate degree from the University of Vermont.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SERNOVA CORP.
1,74% | 25/04/2023 | 5 273 598 ( 1,74% ) | 2 M $ | 31/03/2024 |
Postes actifs de Philip Toleikis
| Sociétés | Poste | Début |
|---|---|---|
| SERNOVA CORP. | Chief Tech/Sci/R&D Officer | 05/09/2023 |
| Medway Working Group | Corporate Officer/Principal | - |
Anciens postes connus de Philip Toleikis
| Sociétés | Poste | Fin |
|---|---|---|
Angiotech Pharmaceuticals, Inc.
 Angiotech Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company, which engages in developing, manufacturing and marketing medical products and technologies, within the areas of interventional oncology, wound closure and ophthalmology. The company was founded by William L. Hunter and Cruz F. Tony in 1992 and is headquartered in Vancouver, Canada. | Chief Tech/Sci/R&D Officer | 01/01/2006 |
Formation de Philip Toleikis
| University of British Columbia | Doctorate Degree |
| University of Michigan | Graduate Degree |
| University of Vermont | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SERNOVA CORP. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Angiotech Pharmaceuticals, Inc.
Angiotech Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company, which engages in developing, manufacturing and marketing medical products and technologies, within the areas of interventional oncology, wound closure and ophthalmology. The company was founded by William L. Hunter and Cruz F. Tony in 1992 and is headquartered in Vancouver, Canada. | Health Technology |
| Medway Working Group |
